



1636

PATENT
Attorney Docket No.: 469188-19
(A-70383-2/RMS/DCF)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Katze, Michael, and Michael Gale

Serial No.: 09/972,756

Filing Date: October 5, 2001

For: *Novel Screening Methods to Identify
Agents That Selectively Inhibit
Hepatitis C Virus Replication*

Examiner: Ketter, James

Art Unit: 1636

CERTIFICATE OF MAILING

I hereby certify that this correspondence, including listed enclosures, are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Box Sequence, Commissioner for Patents, Washington, DC 20231 on:

Dated:

Signed:

Mari Kleineidam

8/C

Zuta

1-28-03

January 16, 2003
Mari Kleineidam

STATEMENT AND PRELIMINARY AMENDMENT RE SEQUENCE LISTING

Box Sequence
Commissioner for Patents
Washington, DC 20231

Sir:

RECEIVED

JAN 24 2003

TECH CENTER 1600/2900

This statement and preliminary amendment is in response to the Office Communication and Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed December 16, 2002 (Paper Number 7), a copy of which is enclosed. This statement and amendment is being mailed within one month of the mailing date of the Notice to Comply, making it a timely response. Please amend the application as follows to correct minor clerical errors and to comply with requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures in adherence with rules 37 C.F.R. § 1.821-1.825: